thalidomide has been researched along with Chondrosarcoma in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Chondrosarcoma: A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has been used to treat a variety of diseases ranging from alleviation of autoimmune disorders to prevention of metastasis of cancers." | 1.33 | Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination. ( Haruta, S; Inagaki, K; Kanayama, N; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Kondo, T; Kurita, N; Sakamoto, Y; Terao, T; Yagyu, T; Yamada, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kobayashi, H | 1 |
| Yagyu, T | 1 |
| Kondo, T | 1 |
| Kurita, N | 1 |
| Inagaki, K | 1 |
| Haruta, S | 1 |
| Kawaguchi, R | 1 |
| Kitanaka, T | 1 |
| Sakamoto, Y | 1 |
| Yamada, Y | 1 |
| Kanayama, N | 1 |
| Terao, T | 1 |
1 other study available for thalidomide and Chondrosarcoma
| Article | Year |
|---|---|
Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chondrosarcoma; Drug Syne | 2005 |